Patients With Haemoglobinopathies and Chronic Hepatitis C: A Really Difficult to Treat Population in 2016?

Zachou, Kalliopi; Arvaniti, Pinelopi; Gatselis, Nikolaos; Papadamou, Georgia; Rigopoulou, Eirini I.; Dalekos, George Ν.

doi:10.4084/mjhid.2017.003

Cited by 12 publications

(18 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…If someone develops a new infection and it has not cleared after eight to twelve weeks, 24 weeks of pegylated interferon therapy is recommended [43]. In people with thalassemia, ribavirin appears to be useful but increases the need for transfusions [44]. Some of the targeted anti-HCV agents (1 to 11) indicated for treatment are shown in Fig.…”

Section: Some Potent Drugs Used For Treat Hepatits C Diseasementioning

confidence: 99%

“…Quinoline derivatives also proven as having an important anti-HCV nature (43, IC 50 ¼ 0.008 nM in the allosteric site of NS5B enzyme) [58]. Pyranoindole (44) and benzimidazole derivatives (45 & 46, IC 50 ¼ 3.5 mM & < 6 nM) [58] are proved to be interacting with the allosteric site [61] of the NS5B target of HCV to exert anti-HCV activity (Fig. 14) [58].…”

Section: Nucleoside Non-nucleoside and Protease Inhibitors As Anti-hmentioning

confidence: 99%

See 1 more Smart Citation

A review on HCV inhibitors: Significance of non-structural polyproteins

Ganta¹,

Gedda

Rathnakar

et al. 2019

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

a b s t r a c tHepatitis C virus (HCV) mortality and morbidity is a world health misery with an approximate 130e150 million chronically HCV tainted and suffering individuals and it initiate critical liver malfunction like cirrhosis, hepatocellular carcinoma or liver HCV cancer. HCV NS5B protein one of the best studied therapeutic target for the identification of new drug candidates to be added to the combination or multiple combination medication recently approved. During the past few years, NS5B has thus been an important object of attractive medicinal chemistry endeavors, which induced to the surfacing of betrothal preclinical drug molecules. In this scenario, the current review set limit to discuss research published on NS5B and few other therapeutic functional inhibitors concentrating on hit investigation, hit to lead optimization, ADME parameters evaluation, and the SAR data which was out for each compound type and similarity taken into consideration. The discussion outlined in this specific review will surly helpful and vital tool for those medicinal chemists investigators working with HCV research programs mainly pointing on NS5B and set broad spectrum identification of creative anti HCV compounds. This mini review also tells each and every individual compound ability related how much they are active against NS5B and few other targets.

show abstract

Section: Some Potent Drugs Used For Treat Hepatits C Diseasementioning

confidence: 99%

Section: Nucleoside Non-nucleoside and Protease Inhibitors As Anti-hmentioning

confidence: 99%

A review on HCV inhibitors: Significance of non-structural polyproteins

Ganta¹,

Gedda

Rathnakar

et al. 2019

European Journal of Medicinal Chemistry

View full text Add to dashboard Cite

show abstract

“…The ages of the patients and control groups were distributed between 1 year to 44 years. The more significant majority of the infected persons with HCV was in the middle age groups (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29) years old, while the lowest rate of infected persons was in the age group (30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44) years of old. Gender did not differ significantly among thalassemia patients with or without HCV infection and healthy subjects (Table2).…”

Section: Molecular Rt-pcr Resultsmentioning

confidence: 99%

“…At a global level, between 4.4 % and 85.4 % of the thalassemia patients are positive for anti-HCV antibodies 18 . The distribution of patients according to age were as follow: 73.0% were in the range of (15-29) years; 18.0% in the range (1-14) yearsand 9% inthe range (30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44) years. In our study, the mean age of thalassaemic patients with anti-HCV was20±7.0 years.…”

Section: Discussionmentioning

confidence: 99%

“…There are apparent differences in the distribution of thalassemia patients infected with hepatitis C according to the age groups. The highest percent of incidence in the age group (15-29 years) as it was estimated at 73% while the lowest percentage is in the age groups (30)(31)(32)(33)(34)(35)(36)(37)(38)(39)(40)(41)(42)(43)(44). This may be because early detection of the disease gives more significant opportunity for treatment and cure.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Role of Oxidative Stress Markers in Î’-Thalassemic Iraqi Patients Infected With Hepatitis C Virus Diagnosed by Rt-PCR

Ani

Al-Ouqaili²,

Awad

2019

Int J Life Sci Pharm Res

View full text Add to dashboard Cite

Blood transfusion is associated with the risk of infection, especially hepatitis C virus and may lead to peroxidative tissue injury by secondary iron overload in β-thalassemic patients. This study aims to detect HCV-RNA copies in thalassemic patients detected by RT-PCR qualitatively and quantitatively. Also, to measure the role of enzymatic and non-enzymatic anti-oxidants markers in β-thalassemia patients infected with HCV. A total of 200 β-thalassemic patients were collected and analyzed for anti-HCV antibodies using Rapid immunochromatographic assay and enzyme-linked Immunosorbent assay methods. Then, the nucleic acids HCV-RNA of positive samples were extracted by modern automated technique. After that, Amplification for HCV-RNA was amplified. The vitamins C and, E in addition to GSH and GGT were also accurately detected. Out of 100 positive ELISA-anti-HCV antibodies, 72(72%) were also positive for RT-PCR considering the assay threshold for the procedure was >13 IU/ ml. The mean viral load in these patients was 545806 ±1009799 IU/ml (1997176 ±3802206) Copies/ml. There was an observed difference (P≤ 0.005) inactivity of TSB, GGT, Protein, Albumin in sera of HCV patients (2.87 ± 1.41, 51.1 ± 60.0 , 6.44 ±2.00 , 3.37 ±0.71) when compared with healthy subjects (0.99 ± 0.46 ; 25.2 ± 12.0 , 7.09 ±0.66 , 3.94 ±0.59) respectively while the Globulin detected evinced no significant difference (P˃ 0.005) in HCV patients (2.90±0.80) as compared with healthy subjects (3.14 ±0.42). Besides there was a significant difference (P≤ 0.005) in serum vitamin C, vitamin E and GSH, between HCV patients groups (57.2 ±46.1, 34.7±14.6, 282.4 ±150.5) and healthy subject groups (73.0 ± 18.0, 44.6 ± 15.6, 353.5± 59.37) respectively. The prevalence of HCV infection was much higher among β-thalassemic patients compared with the healthy blood donors. It is recommended to use nucleic acid based-tests for screening blood donors. The current study shows that there is no correlation between ELISA and viral load in hepatitis C virus infection. On the other hand, Real-Time PCR is a confirmatory diagnostic test and is considered as the golden test for the diagnosis and follow up of hepatitis C virus infection. The HCV infection significantly increases ALT, AST, ALP, GGT, and TSB level above the normal range while vitamins C, E, and GSH decreased considerably

show abstract

Treatment of hepatitis C virus infection with direct‐acting antiviral drugs is safe and effective in patients with hemoglobinopathies

et al. 2017

View full text Add to dashboard Cite

Progression of liver fibrosis in patients with hemoglobinopathies is strongly related to the severity of iron overload and the presence of chronic hepatitis C virus (HCV) infection. Effective iron chelation therapy and HCV infection eradication may prevent liver complications. The European Association for the Study of the Liver guidelines recommend interferon‐free regimens for the treatment of HCV infection in patients with hemoglobinopathies. However, data regarding the use of direct‐acting antiviral drugs (DAAs) in this patient population are few. This observational study evaluated the safety and efficacy of therapy with DAAs in an Italian cohort of patients with hemoglobinopathies, chronic HCV infection and advanced liver fibrosis. Between March 2015 and December 2016, 139 patients received DAAs and completed 12 weeks of follow up after the end of treatment for the evaluation of sustained virological response (12SVR). The 12SVR (93.5%) was comparable with that typically observed in cirrhotic patients without hemoglobinopathies. Three patients died during the period of observation of causes unrelated to DAAs. One patient did not achieve a virological response and five (3.6%) relapsed during 12 weeks of follow‐up after the end of therapy. In addition, patients showed significant reductions in serum ferritin at 12 weeks to levels similar to those observed in a control group of 39 patients with thalassemia major without HCV infection, who adhered to chelation therapy and had no overt iron overload. In conclusion, the use of DAAs appears to be safe and effective in patients with hemoglobinopathies and advanced liver disease due to HCV.

show abstract

Patients With Haemoglobinopathies and Chronic Hepatitis C: A Really Difficult to Treat Population in 2016?

Cited by 12 publications

References 43 publications

A review on HCV inhibitors: Significance of non-structural polyproteins

A review on HCV inhibitors: Significance of non-structural polyproteins

The Role of Oxidative Stress Markers in Î’-Thalassemic Iraqi Patients Infected With Hepatitis C Virus Diagnosed by Rt-PCR

Treatment of hepatitis C virus infection with direct‐acting antiviral drugs is safe and effective in patients with hemoglobinopathies

Contact Info

Product

Resources

About